The EGFR-NSCLC market is expected to grow owing to the approval of new agents such as Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others in frontline and combination settings, rising therapy costs, and increasing testing rates that enable the identification of more patients with EGFR alterations.
LAS VEGAS, Feb. 11, 2026 /PRNewswire/ — DelveInsight’s EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
EGFR-NSCLC Market Summary
Discover the new EGFR-NSCLC treatment @ https://www.delveinsight.com/sample-request/epidermal-growth-factor-receptor-non-small-cell-lung-cancer-market?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the Growth of the EGFR-NSCLC Market
The EGFR-NSCLC clinical trial pipeline includes several drugs in mid- and late-stage development that are expected to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment, including Zipalertinib (Cullinan Oncology/Taiho Pharma), Ivonescimab (Akeso Biopharma/Summit Therapeutics), Sacituzumab Tirumotecan (Merck/Kelun-Biotech), Izalontamab Brengitecan (Bristol-Myers Squibb), Firmonertinib (ArriVent BioPharma), and others.
Cullinan Oncology/Taiho Pharma’s Zipalertinib (CLN-081/TAS6417) is an innovative, orally available, irreversible EGFR inhibitor that, according to preclinical data, selectively and effectively targets cells with EGFR exon 20 insertion (EGFRex20ins) mutations while largely sparing wild-type EGFR-expressing cells, thereby minimizing the toxicities typically linked to wild-type EGFR inhibition. It features a distinct chemical structure designed for strong selectivity toward mutant EGFR and reduced activity against both wild-type EGFR and the closely related HER2 receptor. Zipalertinib holds promise as a potential new standard of care for treating non-small cell lung cancer (NSCLC) with EGFRex20ins mutations.
ArriVent BioPharma’s Firmonertinib is an orally administered, brain-penetrant, mutation-selective EGFR inhibitor with broad activity against both common and uncommon EGFR alterations, including PACC and exon 20 insertion mutations. It is currently being investigated in a global Phase III clinical trial for first-line treatment of NSCLC patients harboring EGFR exon 20 insertion mutations (FURVENT; NCT05607550) and in a global Phase Ib trial assessing its efficacy in patients with EGFR PACC mutations (FURTHER; NCT05364043).
The anticipated launch of these emerging therapies are poised to transform the EGFR-NSCLC market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the EGFR-NSCLC market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the EGFR-NSCLC drugs market @ EGFR-NSCLC Clinical Trials
EGFR is a cellular protein that promotes cell growth. Mutations in the EGFR gene can lead to excessive growth, which may result in cancer. These mutations can take various forms, such as deletions, insertions, or point mutations. In clinical testing, patients may be identified as having an EGFR exon 19 deletion or an EGFR L858R point mutation; these are the most common EGFR mutations and are usually managed in the same way. However, some rarer EGFR mutations in lung cancer are treated differently from the common types. A key example is EGFR exon 20 insertions, which do not respond to standard EGFR-targeted therapies known as tyrosine kinase inhibitors (TKIs).
EGFR-NSCLC Epidemiology Segmentation
The EGFR-NSCLC epidemiology section provides insights into the historical and current EGFR-NSCLC patient pool and forecasted trends for the leading markets. In 2024, EGFR Exon 19 deletions accounted for the highest number of cases, approximately 10,000 in EGFR NSCLC in the US.
The EGFR-NSCLC treatment market report proffers epidemiological analysis for the study period 2020-2034 in the leading markets, segmented into:
Scope of the EGFR-NSCLC Market Report
Download the report to understand the factors driving the EGFR-NSCLC market @ EGFR-NSCLC Market Analysis
EGFR-NSCLC Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key EGFR-NSCLC companies, including Genprex, J INTS Bio, Black Diamond Therapeutics, BlossomHill Therapeutics, Scorpion Therapeutics, Pierre Fabre, Antares Therapeutics, Bayer, A2 Biotherapeutics, BioNTech, Dragonfly Therapeutics, Merus, Taiho Oncology, BeOne Medicines (formerly BeiGene), Ono Pharmaceutical, Avistone Biotechnology, Dizal Pharmaceuticals, Checkpoint Therapeutics, DEKA Biosciences, and Taiho Oncology among others.
Non-Small Cell Lung Cancer Market
Non-Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NSCLC companies including BeiGene, Merus and Partner Therapeutics, Johnson & Johnson Innovative Medicine, Betta Pharma/Xcovery, CStone Pharmaceuticals, Bristol-Myers Squibb, Haihe Biopharma, Taiho Pharmaceutical, Takeda Pharmaceuticals, EMD Serono (Merck KGaA), Eli Lilly and Company, Merck, Regeneron/Sanofi, Ono Pharmaceutical, Novartis, Genentech/Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK among others.
Non-small Cell Lung Cancer Clinical Trial Analysis
Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including ArriVent BioPharma, iTeos Therapeutics, GSK, Incyte, Macrogenics, AstraZeneca, Hutchison MediPharma, Hoffmann-La Roche, Genentech, AnaptysBio, Shanghai Henlius Biotech, Otsuka Pharmaceutical, Bristol-Myers Squibb, OSE Immunotherapeutics, Arcus Biosciences, Gilead Sciences, Pfizer, Cullinan Oncology, Taiho Pharma, ImmunityBio, Jiangsu Hansoh Pharmaceutical, Daiichi Sankyo, Boehringer Ingelheim, Moderna Therapeutics, Merck Sharp & Dohme, Eli Lilly and Company, BeyondSpring, Immutep, Genmab, Imugene, Dizal Pharmaceutical, Regeneron Pharmaceuticals, AbbVie, Candel Therapeutics, among others.
Small Cell Lung Cancer Market
Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key advanced small cell lung cancer companies, including Hoffmann-La Roche, Pharma Mar, Jazz, Daiichi Sankyo, Henlius Biotech, SN BioScience, Merck & Co, AstraZeneca, Advenchen Laboratories, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
View original content:https://www.prnewswire.com/news-releases/egfr-nsclc-market-to-observe-stunning-growth-at-a-cagr-of-9-6-during-the-forecast-period-20252034-delveinsight-302684636.html
